Open AccessExpert consensus on management of metabolic disease in Chinese liver transplant recipients
Author(s) -
Tian Shen,
Zhuang Li,
Xu Sun,
Xin Qi,
ZhiHui Wang,
Ruidong Li,
Wenxiu Chang,
Jiayin Yang,
Yang Yang,
Shusen Zheng
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i27.3851
Subject(s) - medicine , liver transplantation , consensus conference , liver disease , intensive care medicine , medline , transplantation , biology , biochemistry
Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosuppressants. Therefore, optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic disease. The Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent studies. Emphasis is placed on the risk factors of metabolic diseases, the effect of immunosuppressants on metabolic disease, and the prevention and treatment of metabolic diseases.